Seleccionar página

The Vall d’Hebron Institute of Oncology (VHIO) Seeks a Clinical Investigator – Early Drug Development

Reference: 25/2019

Number of vacancies: 1-2

Position description:

We are currently recruiting for one or two oncologists who are interested in working in clinical and translational research, and joining our Phase I program. The successful candidate (s) will be in charge of patients and clinical trials in early drug development, and will also be involved in studies, molecular prescreening, and translational projects carried out at our Unit. Development of Investigator-initiated trials and projects will be very much encouraged, as well as involvement in collaborative research with different VHIO programs and groups.

The duration of contract will be between 1-2 years, based on the appointed candidate (s) prior experience, and may be extended depending on professional merits. Review and selection of candidates will take place over the next couple of weeks. The appointed individual (s) will be expected join our Unit no later than October 2019.

Requirements (degree, experience, additional training):

The candidate must be board certified in medical oncology. Given that the main focus of VHIO’s Research Therapy Research Unit for Molecular Therapy of Cancer – UITM ”la Caixa” is early drug development of targeted therapies, this area should be of keen interest to applicants. Prior experience in clinical research will be favorably considered. Since the successful candidate (s) will deal with patients treated in Phase I trials, the ability to communicate in Spanish is imperative. Good command of English is also required for communication with study sponsors and investigators.


Candidates must submit a curriculum vitae and letter of intent via email: Please also attach a letter of reference, if available.

Review of applications will commence immediately.

General description of the site

The Vall d´Hebron University Hospital (HUVH) is one of the largest hospitals in Spain. Its Medical Oncology Department, directed by Josep Tabernero, provides optimal patient care and leads clinical and basic research of excellence, with a clear focus on translational oncology. The tight bench-bedside-back connectivity, linking basic research with clinical science, seeds and stimulates the development of new scientific and clinical opportunities aimed at ultimately improving outcomes for patients.

The main focus of the UITM is the translation of novel targeted therapies strategies into clinical testing: first-in-human trials, novel combinations of targeted therapies and biomarker-driven studies are our main areas of activity. VHIO’s Phase I program has steadily grown in recognition, and now, with the new facilities at the UITM, it has become one of the largest facilities in Europe in terms of dedicated space, trials and patient recruitment.


We closely collaborate with our tumor-specific units (Breast cancer, GI cancer, etc.), translational research laboratories, Cancer Genomics and Molecular Oncology Groups, teams dedicated to research into cancer stem cells, cell signaling, and resistance to targeted therapies, among others. In addition to our expertise in drug development and clinical trial design, we are also involved in biomarker development (CTC, Pharmacodynamics, etc.), patient-derived xenografts, and molecular analysis of tumors for treatment selection.

About VHIO:

Under the leadership of Josep Tabernero, the Vall d’Hebron Institute of Oncology (VHIO), has established itself as a comprehensive cancer center of proven excellence internationally. It is also thanks to VHIO’s optimal organizational structure based on a purely multidisciplinary and translational model that VHIO talents continue to anticipate and tackle the many unresolved questions in combatting this multifaceted and heterogeneous disease.

Located within the Vall d’Hebron Barcelona Hospital Campus, our researchers closely collaborate and interact with Vall d’Hebron physician-scientists. Translational science and clinical research are therefore tightly connected which promotes superb interaction and teamwork which, in turn, accelerates the bench-bedside-bed cycle of knowledge. This privileged environment affords VHIO direct access to patients as well as the entire spectrum of oncology professionals who care for them, and a second-to-none appreciation of how cancer science can translate into more powerful, targeted treatments and better practice for the care of patients.

VHIO’s pioneering model and programs, coupled with its belief in combining strengths through cross-border collaborations, continue to spur advances in reversing cancer resistance, halting metastatic spread, and more effectively treating even the most undruggable tumor types.

VHIO’s translation toward precision oncology: